Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Magenta Therapeutics, Inc. | d76599dex312.htm |
| EX-31.1 - EX-31.1 - Magenta Therapeutics, Inc. | d76599dex311.htm |
| EX-23.1 - EX-23.1 - Magenta Therapeutics, Inc. | d76599dex231.htm |
| EX-21.1 - EX-21.1 - Magenta Therapeutics, Inc. | d76599dex211.htm |
| EX-10.14.2 - EX-10.14.2 - Magenta Therapeutics, Inc. | d76599dex10142.htm |
| EX-10.10.7 - EX-10.10.7 - Magenta Therapeutics, Inc. | d76599dex10107.htm |
| EX-10.10.5 - EX-10.10.5 - Magenta Therapeutics, Inc. | d76599dex10105.htm |
| EX-10.10.4 - EX-10.10.4 - Magenta Therapeutics, Inc. | d76599dex10104.htm |
| 10-K - 10-K - Magenta Therapeutics, Inc. | d76599d10k.htm |
Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL
FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Magenta Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:
| 1. | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 3, 2021
| /s/ Jason Gardner |
| Jason Gardner, D.Phil. |
| President and Chief Executive Officer |
| (Principal Executive Officer) |
| /s/ Stephen Mahoney |
| Stephen Mahoney |
| Chief Financial and Operating Officer |
| (Principal Financial and Accounting Officer) |